Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain

Current Medical Research and Opinion

Volumn 23, Issue 1, 2007, Pages 17-24

  Iskedjian, Michael ^a,b   Bereza, Basil ^a   Gordon, Allan ^c   Piwko, Charles ^a   Einarson, Thomas R ^a,d,e  

^a PharmIdeas Research and Consulting Inc   (Canada)

^b PharmIdeas USA Inc   (United States)

^c MOUNT SINAI HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e PharmIdeas Research and Consulting Inc   (Canada)

Author keywords

Cannabinoids; Meta analysis; Multiple sclerosis; Pain; Systematic review

Indexed keywords

CANNABIS; DRONABINOL; PLACEBO;

ADULT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA EXTRACTION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MULTIPLE SCLEROSIS; NAUSEA; NEUROPATHIC PAIN; RANDOMIZED CONTROLLED TRIAL; REVIEW; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

CANNABINOIDS; CHI-SQUARE DISTRIBUTION; HUMANS; MULTIPLE SCLEROSIS; NEURALGIA; PAIN; PAIN MEASUREMENT; RANDOMIZED CONTROLLED TRIALS;

EID: 33846662156     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X158066     Document Type: Review

References (44)

1. Bruck G, Stadelmann C. Inflammation and degeneration in multiple sclerosis. Neurol Sci 2003;24(Suppl 5):S265-S267
2. Multiple Sclerosis Society of Canada. MS information - frequently asked questions. Website http://www.mssociety.ca/en/information/faq.htm#1 [accessed: August 17, 2006]
3. Burks J. A review of current medical aspects of multiple sclerosis. J Neurol Rehabil 1992;6:131-9
4. The Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis: part I: cost of illness. Can J Neurol Sci 1998;25:23-30
5. Amato M, Battaglia M, Caputo D, et al. The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J Neurol 2002;249:152-63
6. Whetten-Goldstein K, Sloan F, Goldstein L, Kulas E. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998;4:419-25
7. Henriksson F, Fredrikson S, Masterman T, Jönsson B. Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neurol 2001;8:27-35
8. Miltenburger C, Kobelt G. Quality of life and cost of multiple sclerosis. Clin Neurol Neurosurg 2002;104:272-5
9. Grudzinski A, Hakim Z, Cox E, Bootman J. The economics of multiple sclerosis: distribution of costs and relationship to disease severity. PharmacoEconomics 1999;15:229-40
10. Brichetto G, Messmer Uccelli M, Mancardi G, Solaro C. Symptomatic medication use in multiple sclerosis. Mult Scler 2003;9:458-60
11. Archibald C, McGrath P, Ritvo P. Pain prevalence, severity and impact in a clinical sample of multiple sclerosis patients. Pain 1994;58:89-93
12. Solaro C, Lunardi G, Mancardi G. Pain and MS. Int MS J 2003;10:14-9
13. Ehde D, Gibbons L, Chwastiak L, Bombardier C. Chronic pain in a large community sample of persons with multiple sclerosis. Mult Scler 2003;9:605-11
14. Indaco A, Iachetta C, Nappi C, et al. Chronic and acute pain syndromes in patients with multiple sclerosis. Acta Neurol Scand 1994;16:97-102
15. Moulin D. Pain in central and peripheral demyelinating disorders. Neurol Clin 1998;16:889-97
16. Maloni H. Multiple sclerosis and pain. Consortium for multiple sclerosis. Website http://www.mscare.org/presentations.cfm [accessed: August 8, 2006
17. Holdcroft A, Maze M, Dore C, et al. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract for postoperative pain management. Anesthesiology 2006;104:1040-6
18. Burns TL, Ineck JR. Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. Ann Pharmacother 2006;40:251-60
19. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58
20. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101
21. Jadad A, Moore A, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12
22. Barnes MP. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother 2006;7:607-15
23. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 2004;112:299-306
24. Blake DR, Robson P, Ho M, et al. Preliminary assessment of the efficacy, tolerability and safety of cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 2006;45:50-2
25. Jungmayr P. Multiple sclerosis: dronabinol as analgesic. Deutsche Apoteker Zeitung 2004;144:42-4
26. Karst M, Salim K, Burstein S, et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. J Am Med Assoc 2003;290:1757-62
27. Notcutt W, Price M, Miller R, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia 2004;59:440-52
28. Noyes Jr R, Brunk SF, Avery DA, Canter AC. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 1975;18:84-9
29. Noyes Jr R, Brunk SF, Baram DA, Canter A. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 1975;15:139-43
30. Nurimikko TJ, Serpell MG, Hoggart B, et al. A multicentre, double-blind, randomized, placebo-controlled trial of oro-mucosal cannabis-based medicine in the treatment of neuropathic pain characterized by allodynia. Neurology 2005;64(Suppl 1):A374
31. Rog D, Nurmikko T, Friede T, Young C. Randomized controlled trial of cannabis based medicine in central pain due to multiple sclerosis. Neurology 2005;65:812-9
32. Salim K, Schneider U, Burstein S, et al. Pain measurements and side effect profile of the novel cannabinoid ajulemic acid. Neuropharmacology 2005;48:1164-71
33. Schley M, Legler A, Skopp G, et al. Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. Curr Med Res Opin 2006;22:1269-76
34. Svendsen K, Jensen T, Bach F. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. Br Med J 2004;329:253-60
35. Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004;10:417-24
36. Wade D, Robson P, House H, et al. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003;17:21-9
37. Wade D, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10:434-41
38. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003;362(9395):1517-26
39. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS study: safety and efficacy data for 12 months follow-up. J Neurol Neurosurg Psychiatry 2005;76:1664-9
40. Bosworth T. Clinical study report: a double blind, randomised, parallel group, placebo-controlled trial of a combination of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in patients with multiple sclerosis, followed by an open label assessment and study extension [Study Code: GWMS0001, 1-228. 2003. GW Pharma Ltd]
41. Dempster B. Clinical study report: a multi centre randomised, double blind, placebo controlled, parallel group comparison of the effects of cannabis based medicine standardised extracts over 4 weeks, in patients with chronic refractory pain due to multiple sclerosis or other defects of neurological function [Study Code: GWPS0105, 1-259. 2003. GW Pharma Ltd]
42. Davidson A. Clinical study report: a double blind, randomised, parallel group placebo controlled study of cannabis based medicine extract (CBME) to validate the neuropathic pain scale (NPS) compared with a single pain severity score, in central neuropathic pain in multiple sclerosis [Study Code: GWMS0107, 1-237. 2003. GW Pharma Ltd]
43. Farrar J, Portenoy R, Berlin J, et al. Defining the clinically important difference in pain outcome measures. Pain 2000;88:287-94
44. Pavlopoulos S, Thakur GA, Nikas SP, Makriyannis A. Cannabinoid receptors as therapeutic targets. Curr Pharm Des 2006;12:1751-69